Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy.
暂无分享,去创建一个
S. Hammer | D. Katzenstein | M. Hughes | D. Richman | I. Marschner | V. Johnson | R. D’Aquila | S. Spector | M. Saag | A. Collier | M. Fischl | V. DeGruttola | L. Smeaton | R. Coombs | R. D'Aquila | Michael Hughes
[1] P. Hartigan,et al. Changes in Plasma HIV RNA Levels and CD4+ Lymphocyte Counts Predict Both Response to Antiretroviral Therapy and Therapeutic Failure , 1997, Annals of Internal Medicine.
[2] Roger Detels,et al. Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.
[3] L. Mofenson,et al. The Relationship between Serum Human Immunodeficiency Virus Type 1 (HIV-1) RNA Level, CD4 Lymphocyte Percent, and Long-Term Mortality Risk in HIV-1—Infected Children , 1997 .
[4] M. Fowler,et al. Maternal immunologic and virologic risk factors for infant human immunodeficiency virus type 1 infection: findings from the Women and Infants Transmission Study. , 1997, The Journal of infectious diseases.
[5] Robert W. Coombs,et al. Longitudinal Analysis of Quantitative Virologic Measures in Human Immunodeficiency Virus-Infected Subjects with ⩾400 CD4 Lymphocytes: Implications for Applying Measurements to Individual Patients , 1997 .
[6] S. Hammer,et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. , 1996, The New England journal of medicine.
[7] S. Hammer,et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. , 1996, The New England journal of medicine.
[8] J. Kahn,et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. , 1996, The Journal of infectious diseases.
[9] J. Kahn,et al. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy , 1996 .
[10] J. Bartlett,et al. HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group. , 1996, AIDS.
[11] John W. Mellors,et al. Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.
[12] T. Merigan,et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. , 1996, The New England journal of medicine.
[13] P. Hartigan,et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.
[14] J J Goedert,et al. Natural history of HIV-1 cell-free viremia. , 1995, JAMA.
[15] M. Hirsch,et al. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group. , 1995, Archives of internal medicine.
[16] K. K. Lai,et al. Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine , 1995 .
[17] J. Mellors,et al. Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion , 1995, Annals of Internal Medicine.
[18] C. Loveday,et al. Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count , 1995, The Lancet.
[19] D. Richman,et al. Zidovudine Resistance and HIV-1 Disease Progression during Antiretroviral Therapy , 1995, Annals of Internal Medicine.
[20] J. Coffin,et al. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.
[21] J. Margolick,et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. , 1995, The New England journal of medicine.
[22] D. Ho,et al. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. , 1995, The New England journal of medicine.
[23] D. Kuritzkes,et al. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates , 1994, Journal of clinical microbiology.
[24] J. Sninsky,et al. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection , 1994, Journal of clinical microbiology.
[25] R. Gelman,et al. Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. , 1993, Cytometry.
[26] J. Kagan,et al. Assessment of the effects of instrumentation, monoclonal antibody, and fluorochrome on flow cytometric immunophenotyping: a report based on 2 years of the NIAID DAIDS flow cytometry quality assessment program. , 1993, Clinical immunology and immunopathology.
[27] T. Merigan,et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. , 1992, The New England journal of medicine.
[28] P. Reichelderfer,et al. Cartesian coordinate analysis of viral burden and CD4+ cell count in HIV disease: implications for clinical trial design and analysis. , 1996, Antiviral research.